Number 5: New research shows that denosumab biosimilar SB16 is equivalent to the reference product, Prolia (denosumab), up to ...

A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim ...

Explore groundbreaking developments in biosimilars, including patent lawsuits, new ustekinumab launches, and innovative ...

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and ...

Number 5: Biosimilars promise cost savings and improved patient access in Latin America, yet face significant regulatory and educational barriers hindering their uptake. Number 4: Patients with ...

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and ...

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis treatment, enhancing access and affordability.

Number 5: Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases, and ophthalmic conditions. Number 4: Government price ...

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab ...

Number 5: Sarfaraz K. Niazi, PhD, argues that the FDA can accelerate biosimilar entry by changing guidance under the Biologics Price Competition and Innovation Act (BPCIA) without needing ...

Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates.